HIV coreceptors: From dicovery and designation to new paradigms and promise

European Journal of Medical Research

Volumn 12, Issue 9, 2007, Pages 375-384

  Alkhatib, Ghalib ^a   Berger, Edward A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

AIDS; Antibody; CCR5; CD4; Chemokine; Coreceptor; CXCR4; Entry; Fusion; GPCR; HIV; Maraviroc; Microbicide; Nomenclature; Pathogenesis; Receptor; Resistance; Transmission; Treatment; Tropism; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; COMPLEMENTARY DNA; GLYCOPROTEIN GP 120; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MARAVIROC; MICROBICIDE; RANTES; SELZENTRY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; VIRUS RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DNA LIBRARY; DRUG BINDING SITE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; NONHUMAN; SEXUAL TRANSMISSION; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; VIRUS VIRULENCE; DRUG DESIGN; DRUG EFFECT; METABOLISM; PHYSIOLOGY; REVIEW; VIRUS ENTRY;

ANTI-HIV AGENTS; ANTIGENS, CD4; DRUG DESIGN; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; VIRUS INTERNALIZATION;

EID: 35548998700     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Fauci, A.S., Masur, H., Gelmann, E.P., Markham, P.D., Hahn, B.H., Lane, H.C. (1985) The acquired immunodeficiency syndrome - an update. Annals Of Internal Medicine 102, 800-813.
2. Gallo, R.C., Montagnier, L. (2003) Retrospective: the discovery of HIV as the cause of AIDS. N.Eng.J.Med. 349, 2283-2285.
3. McDougal, J.S., Maddon, P.J., Dalgleish, A.G., Clapham, P.R., Littman, D.R., Godfrey, M., Maddon, D.E., Chess, L., Weiss, R.A., Axel, R. (1986) The T4 glycoprotein is a cell-surface receptor for the AIDS virus. Cold. Spring. Harb.Symp.Quant.Biol. 51 Pt 2, 703-711.
4. Sattentau, Q.J., Moore, J.P. (1993) The role of CD4 in HIV binding and entry. Philos.Trans.R.Soc.Lond. [Biol]. 342, 59-66.
5. Wyatt, R., Sodroski, J. (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888.
6. Eckert, D.M., Kim, P.S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu.Rev.Biochem. 70, 777-810.
7. Maddon, P.J., Dalgleish, A.G., McDougal, J.S., Clapham, P.R., Weiss, R.A., Axel, R. (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47, 333-348.
8. Ashorn, P.A., Berger, E.A., Moss, B. (1990) Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J. Virol. 64, 2149-2156.
9. Clapham, P.R., Blanc, D., Weiss, R.A. (1991) Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. Virology 181, 703-715.
10. Weiner, D.B., Huebner, K., Williams, W.V., Greene, M.I. (1991) Human genes other than CD4 facilitate HIV-1 infection of murine cells. Pathobiology 59, 361-371.
11. Dragic, T., Charneau, P., Clavel, F., Alizon, M. (1992) Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons. J.Virol. 66, 4794-4802.
12. Broder, C.C., Dimitrov, D.S., Blumenthal, R., Berger, E.A. (1993) The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s). Virology 193, 483-491.
13. Miedema, F., Meyaard, L., Koot, M., Klein, M.R., Roos, M.T.L., Groenink, M., Fouchier, R.A.M., Van't Wout, A.B., Tersmette, M., Schellekens, P.T.A., Schuitemaker, H. (1994) Changing virus-host interactions in the course of HIV-1 infection. Immunol.Rev. 140, 35-72.
14. Fenyö, E.M., Fiore, J., Karlsson, A., Albert, J., Scarlatti, G. (1994) Biological phenotypes of HIV-1 in pathogenesis and transmission. Antibiot.Chemother. 46, 18-24.
15. Connor, RI., Ho, D.D. (1994) Transmission and pathogenesis of human immunodeficiency virus type 1. AIDS Res.Hum.Retrovir. 10, 321-323.
16. Berger, E.A. (1997) HIV entry and tropism: the chemokine receptor connection. AIDS 11, Suppl. A, S3-S16.
17. Broder, C.C., Berger, E.A. (1995) Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. Proc.Natl.Acad.Sci. USA 92, 9004-9008.
18. Alkhatib, G., Broder, C.C., Berger, E.A. (1996) Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J.Virol. 70, 5487-5494.
19. Feng, Y., Broder, C.C., Kennedy, P.E., Berger, E.A. (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877.
20. Levy, J.A., Mackewicz, C.E., Barker, E. (1996) Controlling HIV pathogenesis: The role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol.Today. 17, 217-224.
21. Cocchi, F., DeVico, A.L., Garzino-Demo, A., Arya, S.K., Gallo, R.C., Lusso, P. (1995) Identification of RANTES, MIP-1alpha, and MIP-1beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811-1815.
22. Combadiere, C., Ahuja, S.K., Tiffany, H.L., Murphy, P.M. (1996) Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1 (alpha), MIP-1 (beta), and RANTES. J.Leukoc.Biol. 60, 147-152.
23. Samson, M., Labbe, O., Mollereau, C., Vassart, G., Parmentier, M. (1996) Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35, 3362-3367.
24. Deng, H.K., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, S., Sutton, R.E., Hill, C.M., Davis, C.B., Peiper, S.C., Schall, T.J., Littman, D.R., Landau, N.R. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666.
25. Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y.X., Nagashima, K.A., Cayanan, C., Maddon, P.J., Koup, R.A., Moore, J.P., Paxton, W.A. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-673.
26. Alkhatib, G., Combadiere, C., Broder, C.C., Feng, Y., Kennedy, P.E., Murphy, P.M., Berger, E.A. (1996) CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958.
27. Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.D., Wu, L., Mackay, C.R., Larosa, G., Newman, W., Gerard, N., Gerard, C., Sodroski, J. (1996) The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135-1148.
28. Doranz, B.J., Rucker, J., Yi, Y.J., Smyth, R.J., Samson, M., Peiper, S.C., Parmentier, M., Collman, R.G., Doms, R.W. (1996) A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85, 1149-1158.
29. Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski, J., Springer, T.A. (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829-833.
30. Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J.L., Arenzana-Seisdedos, F., Schwartz, O., Heard, J.M., Clark-Lewis, I., Legler, D.F., Loetscher, M., Baggiolini, M., Moser, B. (1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382, 833-835.
31. Murphy, P.M., Baggiolini, M., Charo, I.F., Hebert, C.A., Horuk, R., Matsushima, K., Miller, L.H., Oppenheim, J.J., Power, C.A. (2000) International union of pharmacology. XXII. nomenclature for chemokine receptors. Pharmacol.Rev. 52, 145-176.
32. Wu, L., Gerard, N.P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A., Cardoso, A.A., Desjardin, E., Newman, W., Gerard, C., Sodroski, J. (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384, 179-183.
33. Trkola, A., Dragic, T., Arthos, J., Binley, J.M., Olson,W.C., Allaway, G.P., Cheng-Mayer, C., Robinson, J., Maddon, P.J., Moore, J.P. (1996) CD4-dependent antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384, 184-187.
34. Lapham, C.K., Ouyang, J., Chandrasekhar, B., Nguyen, N.Y., Dimitrov, D.S., Golding, H. (1996) Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 274, 602-605.
35. Berger, E.A., Doms, R.W., Fenyö, E.M., Korber, B.T.M., Littman, D.R., Moore, J.P., Sattentau, Q.J., Schuitemaker, H., Sodroski, J., Weiss, R.A. (1998) A new classification for HIV-1. Nature 391, 240.
36. Moore, J.P., Kitchen, S.G., Pugach, P., Zack, J.A. (2004) The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AidsRes.Hum. Retrovir. 20, 111-126.
37. Lusso, P. (2006) HIV and the chemokine system: 10 years later. Embo J. 25, 447-456.
38. Berger, E.A., Murphy, P.M., Farber, J.M. (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu.Rev.Immunol. 17, 657-700.
39. Simmons, G., Reeves, J.D., Hibbitts, S., Stine, J.T., Gray, P.W., Proudfoot, A.E.I., Clapham, P.R. (2000) Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol.Rev. 177, 112-126.
40. Bandres, J.C., Wang, Q.F., O'Leary, J., Baleaux, F., Amara, A., Hoxie, J.A., Zolla-Pazner, S., Gorny, M.K. (1998) Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J.Virol. 72, 2500-2504.
41. Salzwedel, K., Smith, E.D., Dey, B., Berger, E.A. (2000) Sequential CD4-coreceptor interactions in human immunodeficiency virus type I Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J.Virol. 74, 326-333.
42. Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., Hendrickson, W.A. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659.
43. Chen, B., Vogan, E.M., Gong, H.Y., Skehel, J.J., Wiley, D.C., Harrison, S.C. (2005) Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433, 834-841.
44. Kwong, P.D., Doyle, M.L., Casper, D.J., Cicala, C., Leavitt, S.A., Majeed, S., Steenbeke, T.D., Venturi, M., Chaiken, I., Fung, M., Katinger, H., Parren, P.W.L.H., Robinson, J., Van Ryk, D., Wang, L.P., Burton, D.R., Freire, E., Wyatt, R., Sodroski, J., Hendrickson, W.A., Arthos, J. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682.
45. Rizzuto, C.D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P.D., Hendrickson, W.A., Sodroski, J. (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280, 1949-1953.
46. Wyatt, R., Kwong, P.D., Desjardins, E., Sweet, R.W., Robinson, J., Hendrickson, W.A., Sodroski, J.G. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705-711.
47. Haynes, B.F., Montefiori, D.C. (2006) Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5, 347-363.
48. Pantophlet, R., Burton, D.R. (2006) gp120: target for neutralizing HIV-1 antibodies. Ann.Rev.Immunol. 24, 739-769.
49. Wei, X.P., Decker, J.M., Wang, S.Y., Hui, H.X., Kappes, J.C., Wu, X.Y., Salazar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., Komarova, N.L., Nowak, M.A., Hahn, B.H., Kwong, P.D., Shaw, G.M. (2003) Antibody neutralization and escape by HIV-1. Nature 422, 307-312.
50. Husman, A.M.D., Schuitemaker, H. (1998) Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol. 6, 244-249.
51. Liu, R., Paxton, W.A., Choe, S., Ceradini, D., Martin, S.R., Horuk, R., Macdonald, M.E., Stuhlmann, H., Koup, R.A., Landau, N.R. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377.
52. Samson, M., Libert, F., Doranz, B.J., Rucker,J., Liesnard, C., Farber, C.M., Saragosti, S., Lapoumeroulie, C., Cognaux, J., Forceille, C., Muyldermans, G., Verhofstede, C., Burtonboy, G., Georges, M., Imai, T., Rana, S., Yi, Y.J., Smyth, R.J., Collman, R.G., Doms, R.W., Vassart, G., Parmentier, M. (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722-725.
53. Dean, M., Carrington, M., Winkler, C., Huttley, G.A., Smith, M.W., Allikmets, R., Goedert, J.J., Buchbinder, S.P., Vittinghoff, E., Gomperts, E., Dornfield, S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C., Detels, R., Study, H.G.a.D., Study, M.A.C., Study, M.H.C., Cohort, S.F.C., Study, A., O'Brien, S.J. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856-1862.
54. Zimmerman, P.A., Buckler-White, A., Alkhatib, G., Spalding, T., Kubofcik, J., Combadiere, C., Weissman, D., Cohen, O., Rubbert, A., Lam, G., Vaccarezza, M., Kennedy, P.E., Kumaraswami, V., Giorgi, J.V., Detels, R., Hunter, J., Chopek, M., Berger, E.A., Fauci, A.S., Nutman, T.B., Murphy, P.M. (1997) Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol.Med. 3, 23-35.
55. Hansasuta, P., Rowland-Jones, S.L. (2001) HIV-1 transmission and acute HIV-1 infection. Brit.Med.Bull. 58, 109-127.
56. Carrington, M., O'Brien, S.J. (2003) The influence of HLA genotype on AIDS. Annu.Rev.Med. 54, 535-551.
57. Anastassopoulou, C.G., Kostrikis, L.G. (2003) The impact of human allelic variation on HIV-1 disease. Curr. HIV Res. 1, 185-203.
58. Theodorou, L., Capoulade, C., Combadiere, C., Debre, P. (2003) Genetic control of HIV disease. Trends Microbiol. 11, 392-397.
59. O'Brien, S.J., Nelson, G.W. (2004) Human genes that limit AIDS. Nat. Genet. 36, 565-574.
60. Nolan, D., Gaudieri, S., John, M., Mallal, S. (2004) Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground. AIDS 18, 1231-1240.
61. Kaslow, R.A., Dorak, T., Tang, J. (2005) Influence of host genetic variation on susceptibility to HIV type 1 infection. J. Infect.Dis. 191, S68-S77.
62. Shioda, T., Nakayama, E.E. (2006) Human genetic polymorphisms affecting HIV-1 diseases. Int.J.Hematol. 84, 12-17.
63. Heeney, J.L., Dalgleish, A.G., Weiss, R.A. (2006) Origins of HIV and the evolution of resistance to AIDS. Science 313, 462-466.
64. O'Brien, S.J., Moore, J.P. (2000) The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol.Rev. 177, 99-111.
65. Lehner, T. (2002) The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol. 23, 347-351.
66. Arenzana-Seisdedos, F., Parmentier, M. (2006) Genetics of resistance to HIV infection: role of co-receptors and co-receptor ligands. Seminars In Immunology 18, 387-403.
67. Garzino-Demo, A. (2007) Chemokines and defensins as HIV suppressive factors: an evolving story. Curr.Pharm. Design 13, 163-172.
68. Agrawal, L., Lu, X.H., Qingwen, J., Vanhorn-Ali, Z., Nicolescu, IV., McDermott, D.H., Murphy, P.M., Alkhatib, G. (2004) Role for CCR5 delta 32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4(+) cells. J.Virol. 78, 2277-2287.
69. Lim, J.K., Glass, W.G., McDermott, D.H., Murphy, P.M. (2006) CCR5: no longer a 'good for nothing' gene-chemokine control of West Nile virus infection. Trends Immunol. 27, 308-312.
70. Schols, D. (2006) HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antivir.Res. 71, 216-226.
71. Palani, A., Tagat, JR. (2006) Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists. J.Medic.Chem. 49, 2851-2857.
72. Agrawal, L., Lu, X.H., Jin, Q.W., Alkhatib, G. (2006) Anti-HIV therapy: current and future directions. Curr.Pharm.Design 12, 2031-2055.
73. Ray, N., Doms, R.W. (2006) HIV-1 coreceptors and their inhibitors. Curr.Top.Microbiol.Immunol. 303, 97-120.
74. Lederman, M.M., Penn-Nicholson, A., Cho, M., Mosier, D. (2006) Biology of CCR5 and its role in HIV infection and treatment. J.Amer.Med.Assoc. 296, 815-826.
75. Repik, A., Richards, K.H., Clapham, P.R. (2007) The promise of CCR5 antagonists as new therapies for HIV-1. Curr,Opin.Invest. Drugs 8, 130-139.
76. Tsibris, A.M.N., Kuritzkes, D.R. (2007) Chemokine antagonists as therapeutics: focus on HIV-1. Ann.Rev.Med. 58, 445-459.
77. Biswas, P., Tambussi, G., Lazzarin, A. (2007) Access denied? the status of co-receptor inhibition to counter HIV entry. Expert Opin.Pharmacother. 8, 923-933.
78. Trkola, A., Kuhmann, S.E., Strizki,J.M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., Palani, A., Shapiro, S., Clader, J.W., McCombie, S., Reyes, G.R., Baroudy, B.M., Moore, J.P. (2002) HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc.Natl.Acad.Sci.USA 99, 395-400.
79. Marozsan, A.J., Kuhmann, S.E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B.M., Strizki, J., Moore, J.P. (2005) Generation and properties of a human immunodeficiency virus type i isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338, 182-199.
80. Westby, M., Mori, J., Smith-Burchnell, C., Lewis, M., Mosley, M., Perruccio, F., Mansfield, R., Dorr, P., Perros, M. (2005) Maraviroc (UK-427,857)-resistant HIV-1 variants, selected by serial passage, are sensitive to CCR5 antagonists and T-20. Antiviral Therapy 10, S72-S72.
81. Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G., Perros, M. (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J.Virol. 81, 2359-2371.
82. Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A.L., James, I.T., Jenkins, T.M., Perros, M., van der Ryst, E. (2006) Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J.Virol. 80, 4909-4920.
83. Decker, J.M., Bibollet-Ruche, F., Wei, X.P., Wang, S.Y., Levy, D.N., Wang, W.Q., Delaporte, E., Peeters, M., Derdeyn, C.A., Allen, S., Hunter, E., Saag, M.S., Hoxie, J.A., Hahn, B.H., Kwong, P.D., Robinson, J.E., Shaw, G.M. (2005) Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201, 1407-1419.
84. Dey, B., Del Castillo, C.S., Berger, E.A. (2003) Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J.Virol. 77, 2859-2865.
85. Lederman, M.M., Offord, R.E., Hartley, O. (2006) Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nature Rev.Immunol. 6, 371-382.
86. Veazey, R.S., Klasse, P.J., Ketas, T.J., Reeves,J.D., Piatak, M., Kunstman, K., Kuhmann, S.E., Marx, P.A., Lifson, J.D., Dufour, J., Mefford, M., Pandrea, I., Wolinsky, S.M., Doms, R.W., DeMartino, J.A., Siciliano, S.J., Lyons, K., Springer, MS., Moore, J.P. (2003) Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J.Exp.Med. 198, 1551-1562.
87. Lederman, M.M., Veazey, R.S., Offord, R., Mosier, D.E., Dufour,J., Mefford, M., Piatak, M., Lifson, J.D., Salkowitz, J.R., Rodriguez, B., Blauvelt, A., Hartley, O. (2004) Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306, 485-487.
88. Dragic, T. (2001) An overview of the determinants of CCR5 and CXCR4 co-receptor function. J.Gen.Virol. 82, 1807-1814.
89. Hartley, O., Klasse, P.J., Sattentau, Q.J., Moore, J.P. (2005) V3: HIV's switch-hitter. AIDS Res.Hum.Retrovir. 21, 171-189.
90. Anastassopoulou, C.G., Kostrikis, L.G. (2005) Viral correlates of HIV-1 disease. Curr.HIV Res. 3, 113-132.
91. Margolis, L., Shattock, R. (2006) Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat. Rev. Microbiol. 4, 312-317.
92. Lusso, P., Earl, P.L., Sironi, F., Santoro, F., Ripamonti, C., Scarlatti, G., Longhi, R., Berger, E.A., Burastero, S.E. (2005) Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J.Virol. 79, 6957-6968.
93. Bunnik, E.M., Quakkelaar, E.D., van Nuenen, A.C., Boeser-Nummink, B., Schuitemaker, H. (2007) Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J.Virol. 81, 525-531.
94. Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., Perros, M. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732.
95. (2007) FDA approves novel antiretroviral drug. FDA News, http://www.fda.gov/bbs/topics/NEWS/2007/NEW01677.html